Long-term Safety and Efficacy of Efgartigimod in Patients With Generalised Myasthenia Gravis

被引：0
|
作者：
Meisel, A. [1 ,2 ]
Bril, V. [3 ,4 ]
Vu, T. [5 ]
Karam, C. [6 ]
Peric, S. [7 ]
De Bleecker, J. [8 ]
Murai, H. [9 ]
Beydoun, S. [10 ]
Pasnoor, M. [11 ]
Guglietta, A. [12 ]
Ulrichts, P. [12 ]
T'joen, C. [12 ]
Utsugisawa, K. [13 ]
Verschuuren, J. [14 ]
Mantegazza, R. [15 ]
Howard, J. [16 ]
机构：
[1] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[2] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany
[3] Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL USA
[6] Univ Penn, Penn Neurosci Ctr, Philadelphia, PA USA
[7] Univ Belgrade, Univ Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia
[8] Ghent Univ Hosp, Ghent, Belgium
[9] Int Univ Hlth & Welf, Sch Med, Dept Neurol, Tokyo, Japan
[10] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[11] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[12] Argenx, Ghent, Belgium
[13] Hanamaki Gen Hosp, Dept Neurol, Hanamaki, Japan
[14] Leiden Univ, Dept Neurol, Med Ctr, Leiden, Netherlands
[15] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
[16] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27515 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
OPR-021
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [41] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial (vol 20, pg 526, 2021)
    Jf, Howard, Jr.
    Bril, V
    Vu, T.
    [J]. LANCET NEUROLOGY, 2021, 20 (08): : E5 - E5
  • [42] Long-term cyclosporine treatment in a group of severe myasthenia gravis patients
    Bonifati, DM
    Angelini, C
    [J]. JOURNAL OF NEUROLOGY, 1997, 244 (09) : 542 - 547
  • [43] Long-term prognosis of patients with thymoma-associated myasthenia gravis
    Schalke, BCG
    Schmitt, I
    Marx, A
    Toyka, K
    MullerHermelink, HK
    [J]. EPITHELIAL TUMORS OF THE THYMUS: PATHOLOGY, BIOLOGY, TREATMENT, 1997, : 329 - 335
  • [44] LONG-TERM EFFECTS OF TREATMENT IN 374 PATIENTS WITH MYASTHENIA-GRAVIS
    OOSTERHUIS, HJGH
    [J]. MONOGRAPHS IN ALLERGY, 1988, 25 : 75 - 85
  • [45] Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients
    Keung, Benison
    Robeson, Kimberly R.
    DiCapua, Daniel B.
    Rosen, Jennifer B.
    O'Connor, Kevin C.
    Goldstein, Jonathan M.
    Nowak, Richard J.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (12): : 1407 - +
  • [46] Long-term follow-up of myasthenia gravis patients with hyperthyroidism
    Ratanakorn, D
    Vejjajiva, A
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (02): : 93 - 98
  • [47] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
  • [48] Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
    Antozzi, Carlo
    Guptill, Jeffrey
    Bril, Vera
    Gamez, Josep
    Meuth, Sven G.
    Nowak, Richard J.
    Quan, Dianna
    Sevilla, Teresa
    Jouvin, Marie-Helene
    Jin, Jim
    Karcher, Keith
    Ramchandren, Sindhu
    Sun, Hong
    Ling, Leona
    Zhu, Yaowei
    Arroyo, Santiago
    [J]. NEUROLOGY, 2024, 102 (02)
  • [49] Real-World experience with efgartigimod in patients with myasthenia gravis
    Fuchs, Lior
    Shelly, Shahar
    Vigiser, Ifat
    Kolb, Hadar
    Regev, Keren
    Schwartzmann, Yoel
    Vaknin-Dembinsky, Adi
    Dori, Amir
    Karni, Arnon
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (06) : 3462 - 3470
  • [50] Long-Term Safety, Tolerability, And Efficacy of Efgartigimod In Patients With gMG: Final Analyses From The ADAPT plus Study
    Meisel, A.
    De Bleecker, J.
    Verschuuren, J.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Murai, H.
    Beydoun, S.
    Pasnoor, M.
    Steeland, S.
    Van Hoorick, B.
    T'joen, C.
    Utsugisawa, K.
    Mantegazza, R.
    Howard, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 208 - 209
12345